ARTICLE | Product Development
Lonza to manufacture Moderna COVID-19 vaccine, lifting annual capacity to 1B doses
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
May 1, 2020 4:56 AM UTC
Updated on May 2, 2020 at 3:48 AM UTC
Moderna has secured mass manufacturing capacity for its COVID-19 candidate vaccine through a deal with Lonza and is already scoping out a Phase III trial design, Moderna CEO Stéphane Bancel told BioCentury.
The deal comes in the same week that AstraZeneca plc (LSE:AZN; NYSE:AZN) and Serum Institute of India announced plans to mass produce a COVID-19 vaccine that Oxford University’s Jenner Institute is developing (see “AstraZeneca to Make COVID-19 Vaccine” and “India Emerging as Major COVID-19 Vaccine Manufacturer”). ...